Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.

Standard

Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. / Winchester, B; Bali, D; Bodamer, O A; Caillaud, C; Christensen, E; Cooper, A; Cupler, E; Deschauer, M; Fumi, K; Jackson, M; Kishnani, P; Lacerda, L; Ledvinová, J; Lugowska, A; Lukacs, Zoltan; Maire, I; Mandel, H; Mengel, E; Müller-Felber, W; Piraud, M; Reuser, A; Rupar, T; Sinigerska, I; Szlago, M; Verheijen, F; van Diggelen, O P; Wuyts, B; Zakharova, E; Keutzer, J.

in: MOL GENET METAB, Jahrgang 93, Nr. 3, 3, 2008, S. 275-281.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Winchester, B, Bali, D, Bodamer, OA, Caillaud, C, Christensen, E, Cooper, A, Cupler, E, Deschauer, M, Fumi, K, Jackson, M, Kishnani, P, Lacerda, L, Ledvinová, J, Lugowska, A, Lukacs, Z, Maire, I, Mandel, H, Mengel, E, Müller-Felber, W, Piraud, M, Reuser, A, Rupar, T, Sinigerska, I, Szlago, M, Verheijen, F, van Diggelen, OP, Wuyts, B, Zakharova, E & Keutzer, J 2008, 'Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.', MOL GENET METAB, Jg. 93, Nr. 3, 3, S. 275-281. <http://www.ncbi.nlm.nih.gov/pubmed/18078773?dopt=Citation>

APA

Winchester, B., Bali, D., Bodamer, O. A., Caillaud, C., Christensen, E., Cooper, A., Cupler, E., Deschauer, M., Fumi, K., Jackson, M., Kishnani, P., Lacerda, L., Ledvinová, J., Lugowska, A., Lukacs, Z., Maire, I., Mandel, H., Mengel, E., Müller-Felber, W., ... Keutzer, J. (2008). Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. MOL GENET METAB, 93(3), 275-281. [3]. http://www.ncbi.nlm.nih.gov/pubmed/18078773?dopt=Citation

Vancouver

Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. MOL GENET METAB. 2008;93(3):275-281. 3.

Bibtex

@article{b05e65021f5244358e6764736f1072e2,
title = "Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.",
abstract = "Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data generated using the new methods, and to establish a consensus regarding the application of the methods for the laboratory diagnosis of Pompe disease. Skin fibroblasts and muscle biopsy have traditionally been the samples of choice for measuring GAA activity. However, new methods using blood samples are rapidly becoming adopted because of their speed and convenience. Measuring GAA activity in blood samples should be performed under acidic conditions (pH 3.8-4.0), using up to 2 mM of the synthetic substrate 4-methylumbelliferyl-alpha-D-glucoside or glycogen (50 mg/mL), in the presence of acarbose (3-9 microM) to inhibit the isoenzyme maltase-glucoamylase. The activity of a reference enzyme should also be measured to confirm the quality of the sample. A second test should be done to support the diagnosis of Pompe disease until a program for external quality assurance and proficiency testing of the enzymatic diagnosis in blood is established.",
author = "B Winchester and D Bali and Bodamer, {O A} and C Caillaud and E Christensen and A Cooper and E Cupler and M Deschauer and K Fumi and M Jackson and P Kishnani and L Lacerda and J Ledvinov{\'a} and A Lugowska and Zoltan Lukacs and I Maire and H Mandel and E Mengel and W M{\"u}ller-Felber and M Piraud and A Reuser and T Rupar and I Sinigerska and M Szlago and F Verheijen and {van Diggelen}, {O P} and B Wuyts and E Zakharova and J Keutzer",
year = "2008",
language = "Deutsch",
volume = "93",
pages = "275--281",
journal = "MOL GENET METAB",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.

AU - Winchester, B

AU - Bali, D

AU - Bodamer, O A

AU - Caillaud, C

AU - Christensen, E

AU - Cooper, A

AU - Cupler, E

AU - Deschauer, M

AU - Fumi, K

AU - Jackson, M

AU - Kishnani, P

AU - Lacerda, L

AU - Ledvinová, J

AU - Lugowska, A

AU - Lukacs, Zoltan

AU - Maire, I

AU - Mandel, H

AU - Mengel, E

AU - Müller-Felber, W

AU - Piraud, M

AU - Reuser, A

AU - Rupar, T

AU - Sinigerska, I

AU - Szlago, M

AU - Verheijen, F

AU - van Diggelen, O P

AU - Wuyts, B

AU - Zakharova, E

AU - Keutzer, J

PY - 2008

Y1 - 2008

N2 - Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data generated using the new methods, and to establish a consensus regarding the application of the methods for the laboratory diagnosis of Pompe disease. Skin fibroblasts and muscle biopsy have traditionally been the samples of choice for measuring GAA activity. However, new methods using blood samples are rapidly becoming adopted because of their speed and convenience. Measuring GAA activity in blood samples should be performed under acidic conditions (pH 3.8-4.0), using up to 2 mM of the synthetic substrate 4-methylumbelliferyl-alpha-D-glucoside or glycogen (50 mg/mL), in the presence of acarbose (3-9 microM) to inhibit the isoenzyme maltase-glucoamylase. The activity of a reference enzyme should also be measured to confirm the quality of the sample. A second test should be done to support the diagnosis of Pompe disease until a program for external quality assurance and proficiency testing of the enzymatic diagnosis in blood is established.

AB - Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data generated using the new methods, and to establish a consensus regarding the application of the methods for the laboratory diagnosis of Pompe disease. Skin fibroblasts and muscle biopsy have traditionally been the samples of choice for measuring GAA activity. However, new methods using blood samples are rapidly becoming adopted because of their speed and convenience. Measuring GAA activity in blood samples should be performed under acidic conditions (pH 3.8-4.0), using up to 2 mM of the synthetic substrate 4-methylumbelliferyl-alpha-D-glucoside or glycogen (50 mg/mL), in the presence of acarbose (3-9 microM) to inhibit the isoenzyme maltase-glucoamylase. The activity of a reference enzyme should also be measured to confirm the quality of the sample. A second test should be done to support the diagnosis of Pompe disease until a program for external quality assurance and proficiency testing of the enzymatic diagnosis in blood is established.

M3 - SCORING: Zeitschriftenaufsatz

VL - 93

SP - 275

EP - 281

JO - MOL GENET METAB

JF - MOL GENET METAB

SN - 1096-7192

IS - 3

M1 - 3

ER -